Dr. William Gradishar, M.D.
Claim this profileNorthwestern University
Area of expertise
Breast Cancer
William Gradishar, M.D. has run 9 trials for Breast Cancer. Some of their research focus areas include:
Breast Cancer
William Gradishar, M.D. has run 4 trials for Breast cancer. Some of their research focus areas include:
Affiliated Hospitals
Northwestern University
Northwestern Medicine Lake Forest Hospital
Clinical Trials William Gradishar, M.D. is currently running
Elacestrant vs Elacestrant + CDK4/6 Inhibitor
for Breast Cancer
Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negative breast cancer is the most prevalent breast cancer subtype. Endocrine therapy is the mainstay of treatment; however, due to the varied nature of the disease, development of resistance to this therapeutic approach is very common in the metastatic setting. The purpose of this study is to see whether the effectiveness of elacestrant can be enhanced by combining it with a targeted agent such as a CDK4/6 inhibitor to treat patients with ER+/HER2- or metastatic breast cancer with prior exposure to a CDK4/6 inhibitor.
Recruiting
1 award
Phase 2
14 criteria
Elacestrant Combinations
for Breast Cancer
This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the recommended Phase 2 dose (RP2D) of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, capivasertib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations.
Recruiting
1 award
Phase 1 & 2
More about William Gradishar, M.D.
Clinical Trial Related
2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments William Gradishar, M.D. has experience with
- Elacestrant
- Palbociclib
- Ribociclib
- Trastuzumab
- Paclitaxel
- Pertuzumab
Breakdown of trials William Gradishar, M.D. has run
Breast Cancer
Breast cancer
Pancreatic Cancer
HER2-Positive Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does William Gradishar, M.D. specialize in?
William Gradishar, M.D. focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 negative.
Is William Gradishar, M.D. currently recruiting for clinical trials?
Yes, William Gradishar, M.D. is currently recruiting for 5 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that William Gradishar, M.D. has studied deeply?
Yes, William Gradishar, M.D. has studied treatments such as Elacestrant, Palbociclib, Ribociclib.
What is the best way to schedule an appointment with William Gradishar, M.D.?
Apply for one of the trials that William Gradishar, M.D. is conducting.
What is the office address of William Gradishar, M.D.?
The office of William Gradishar, M.D. is located at: Northwestern University, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.